Docetaxel combined with targeted therapies in metastatic breast cancer

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 387-396

  Cortes, Javier ^a   Roché, Henri ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Bevacizumab; Breast cancer; Docetaxel; Metastatic; Targeted therapy; Trastuzumab

Indexed keywords

AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMATINIB; LAPATINIB; METHOTREXATE; MITOMYCIN; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TANESPIMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VINBLASTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COST; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; PYRROLES; QUINAZOLINES; TAXOIDS;

EID: 84861196060     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.08.001     Document Type: Review

References (94)

1. Carrick S., Parker S., Wilcken N., et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews 2009, Issue 2. Copyright©. The Cochrane Collaboration 2009, John Wiley & Sons Ltd., Chichester.
2. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20-37.
3. Ghersi D., Wilcken N., Simes J., Donoghue E. Taxane containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. Copyright©. The Cochrane Collaboration 2009, John Wiley & Sons Ltd., Chichester.
4. Bonneterre J., Roche H., Monnier A., et al. Docetaxel versus 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002, 87:1210-1215.
5. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2354.
6. Jones S.E., Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23:5542-5551.
7. Nabholtz J.M., Senn H.J., Bezwoda W.R., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline containing chemotherapy. 304 Study Group. J Clin Oncol 1999, 17:1413-1424.
8. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.
9. Sjöstrom J., Blomqvist C., Mouridsen H., et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194-1201.
10. Nabholtz J.M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21:968-975.
11. Bontenbal M., Creemers G.J., Braun H.J., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005, 23:7081-7088.
12. Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005, 353:1734-1736.
13. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
14. Slamon D. Biologic approaches to managing advanced breast cancer. Cancer Control 1999, 6(Suppl. 2):7-11.
15. Sato J.D., Kawamoto T., Le A.D., et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1:511-529.
16. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
17. Jain R.K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002, 29:3-9.
18. Brem S.S., Jensen H.M., Gullino P.M. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978, 41:239-244.
19. Jensen H.M., Chen I., DeVault M.R., Lewis A.E. Angiogenesis induced "normal" human breast tissue: a probable marker for precancer. Science 1982, 218:293-295.
20. Lichtenbeld H.C., Barendsz-Janson A.F., van Essen H., et al. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int J Cancer 1998, 77:455-459.
21. Fox S.B., Gatter K.C., Bicknell R., et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993, 53:4161-4163.
22. Kakolyris S., Fox S.B., Koukourakis M., et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000, 82:844-851.
23. Neufeld G., Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006, 25:373-385.
24. Roskoski R. Vascular endothelial growth factor (VEGF) signalling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213.
25. Barrios C.H., Liu M.C., Lee S.C., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
26. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010;28(Suppl. 18s):abstract LBA1011.
27. Montemurro F., Choa G., Faggiuolo R., et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004, 66:38-45.
28. Tedesco K.L., Thor A.D., Johnson D.H., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004, 22:1071-1077.
29. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
30. Hamberg P., Bos M.M., Braun H.J., et al. Randomized phase II study comparing efficacy and safety of combination therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011, 11:103-113.
31. Ramaswamy B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006, 12:3124-3129.
32. Hurvitz S.A., Allen H.J., Moroose R.L., et al. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer 2010, 10:307-312.
33. ClinicalTrials.gov [homepage on the Internet]. Study of SU011248 in combination with docetaxel in patients with metastatic breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
34. Mariani G, Cardoso F, Besse-Hammer T, et al. Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation. J Clin Oncol 2008;26(Suppl.):abstract 14534.
35. Wildiers C., Fontaine C., Vuylsteke P., et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010, 123:463-469.
36. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010;28(Suppl. 18s):abstract LBA1010.
37. Yardley D.A., Burris H.A., Markus T., et al. Phase II trial of docetaxel plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer 2009, 9:237-242.
38. Wardley A.M., Pivot X., Morales-Vasquez F., et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28:976-983.
39. Valero V., Forbes J., Pegram M.D., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011, 29:149-156.
40. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
41. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
42. Smith I.E., Pierga J.Y., Biganzoli L., et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol 2011, 22:595-602.
43. ClinicalTrials.gov [homepage on the Internet]. GW572016 with docetaxel and trastuzumab for the treatment of untreated erbb2 over-expressing metastatic breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
44. ClinicalTrials.gov [homepage on the Internet]. Lapatinib in combination with docetaxel in patients with HER-2 positive advanced or metastatic breast cancer (LapDoc). 2011 [accessed 6.07.11]. http://www.clinicaltrials.gov.
45. ClinicalTrials.gov [homepage on the Internet]. A phase II, randomized, open-label study of lapatinib plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive and p95HER2-positive metastatic breast cancer. 2011 [accessed 6.07.11]. http://www.clinicaltrials.gov.
46. ClinicalTrials.gov [homepage on the Internet]. Chemotherapy and lapatinib or trastuzumab in treating women with HER2/neu-positive metastatic breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
47. ClinicalTrials.gov [homepage on the Internet]. Study of SU011248 in combination with docetaxel and trastuzumab in patients with advanced breast cancer HER-2 positive. 2011 [accessed 6.07.11]. http://www.clinicaltrials.gov.
48. ClinicalTrials.gov [homepage on the Internet]. Study of SU011248 versus chemotherapy for patients with previously treated triple negative breast cancer. 2011 [accessed 6.07.11]. http://www.clinicaltrials.gov.
49. ClinicalTrials.gov [homepage on the Internet]. SU011248 in treating women with metastatic breast cancer that did not respond to anthracycline or taxane chemotherapy. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
50. ClinicalTrials.gov [homepage on the Internet]. Docetaxel and imatinib mesylate in treatment patients with locally advanced or metastatic breast cancer. 2011 [accessed 6.07.11]. http://www.clinicaltrials.gov.
51. ClinicalTrials.gov [homepage on the Internet]. Study to evaluate pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated Her2-positive metastatic breast cancer (CLEOPATRA). 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
52. ClinicalTrial.gov [homepage on the Internet]. Erlotinib plus docetaxel in treating patients with stage IV or recurrent breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
53. ClinicalTrials.gov [homepage on the Internet]. Erlotinib plus chemotherapy for treatment of triple negative breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
54. ClinicalTrials.gov [homepage on the Internet]. RAD001 plus docetaxel in patients with metastatic breast cancer. 2011 [accessed 4.01.11]. http://www.clinicaltrials.gov.
55. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
56. Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749.
57. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4years in the M77001 study. Abstract 2067 presented at 29th San Antonio Breast Cancer Symposium, 14-17 December 2006. San Antonio, Texas.
58. Gerber H.P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005, 65:671-680.
59. Sweeney C.J., Miller K.D., Sissons S.E., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369-3372.
60. Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur. J. Cancer; 2011 [EPub ahead of print].
61. Biganzoli L, Cortes-Funes H, Thomssen C, et al. Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): subpopulation analysis of the MO19391 study. J Clin Oncol 2009;27(Suppl. 15):abstract 1032.
62. Food and Drug Administration [homepage on the internet]. 2011 [accessed 28.07.11]. http://www.fda.gov.
63. European Medicines Agency [homepage on the internet]. 2011 [accessed 28.07.11]. http://www.ema.europa.eu.
64. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21:6255-6263.
65. Zhou H., Kim Y.S., Peletier A., McCall W., Earp H.S., Sartor C.I. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004, 58:344-352.
66. Konecny G.E., Venkatesan N., Yang G., et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008, 98:1076-1084.
67. LoRusso P.M., Jones S.F., Koch K.M., et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008, 26:3051-3056.
68. Von Minckwitz G., Eldtmann H., Loibl S., et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011, 22:301-306.
69. Chu D., Lu J. Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol 2008, 1:16.
70. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
71. Baselga J., Gelmon K.A., Verma S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
72. Moyer J.D., Barbacci E.G., Iwata K.K., et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838-4848.
73. Pollack V.A., Savage D.M., Baker D.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999, 291:739-748.
74. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
75. Kaur H, Silverman P, Singh D, et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol 2006;24(Suppl. 18):abstract 10623.
76. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003, 2:1011-1021.
77. Robert F., Sandler A., Schiller J.H., et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010, 66:669-680.
78. Liljegren A., Bergh J., Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 2009, 18:259-262.
79. Cardoso F., Senkus-Konefka E. Sunitinib in breast cancer: friend or foe. Breast 2009, 18:211-222.
80. Wilmes L.J., Pallavicini M.G., Fleming L.M., et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007, 25:319-327.
81. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1-3. Clin Cancer Res 2008, 14:7272-7283.
82. Rugo H.S., Stopeck A., Joy A.A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29:2459-2465.
83. Kübler H.R., van Randenborgh H., Treiber U., et al. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 2005, 63:385-394.
84. Connolly R.M., Rudek M.A., Garrett-Mayer E., et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011, 127:153-162.
85. Haley BB, Ashfaq R, DeHaas M, Ramaswami A, Sikder K, Tripathy D. A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer. J Clin Oncol 2007;25(Suppl.):abstract 11039.
86. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
87. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005, 11:5319-5328.
88. Shinohara E.T., Cao C., Niermann K., et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005, 24:5414-5422.
89. O'Reilly T.M., Wood J.M., Amanda L.-E., et al. Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: a rational basis for combining RAD001, PTK787/ZK222584. Proc Am Assoc Cancer Res 2005, 46:715. [Abstract 3038].
90. Moulder SL, Rivera E, Ensor J, et al. Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl. 15):abstract 1066.
91. Tripathy D., Slamon D.J., Cobleigh M., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22:1063-1070.
92. Montemurro F., Donadio M., Clavarezza M., et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006, 11:318-324.
93. Cortes J., Baselga J. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. J Clin Oncol 2009, 27:5492-5494.
94. Genentech press release July 2011: Pertuzumab combined with herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse http://www.gene.com.